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Kentucky.METHODS: Regression models were calculated to predict methamphet-
amine-related hospitalizations from 2010 county level Kentucky data. Explanatory
factors include PSE sales (in grams), number of clandestine lab incidents reported,
USDA urban/rural indicator, methamphetamine-related arrests, number of con-
trolled substance (CS) prescriptions dispensed, and population. Data sources in-
clude the Kentucky All Schedule Prescription Electronic Reporting Program, the
Kentucky Inpatient Discharge Data Set, the Kentucky State Policy Crime in Ken-
tucky Report, and Clandestine Laboratory Surveillance System. RESULTS: PSE sales
were not associated with methamphetamine-related hospitalizations in this
model. The number of clandestine lab incidents reported, however, has a strong
positive impact on methamphetamine-related hospitalizations (p0.001). Meth-
amphetamine-related arrests also have a strong positive relationship to hospital-
ization (p0.001). Finally, use of controlled substances has a small but negative
impact on methamphetamine-related hospitalization (p0.05). CONCLUSIONS:
PSE sales data alone cannot be used to predictmethamphetamine use as evidenced
by methamphetamine-related hospitalizations. The number of clandestine lab in-
cidents, however, reported is strongly associated with methamphetamine-related
hospitalizations. These findings suggest that policies aimed at reducing clandes-
tine labs may have a significant impact on indicators of methamphetamine use.
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COMPARISON OF TOTAL HEALTH CARE COSTS BETWEEN REMITTERS AND
NON-REMITTERS FOR SCHIZOPHRENIA PATIENTS FROM A PROSPECTIVE
LONGITUDINAL, OBSERVATIONAL STUDY IN THE PRESENCE OF MISSING DATA
Zhu B, Xu L, Faries D, Shen W, Haynes V
Eli Lilly and Company, Inc., Indianapolis, IN, USA
OBJECTIVES:Missing data has presented challenges to health economic analyses,
especially for a long-term observational study with repeated measures of clinical
and economic outcomes. The aim of this analysis was to compare the total health
care costs between symptom remission and non-remission from a long-term, ob-
servational study using mixed-effects models with and without multiple imputa-
tions (MI) of missing data. METHODS: Data (N2282) used for this analysis were
from a 3-year observational study of patients treated for schizophrenia in the
United States between July 1997 and September 2003. Costs of mental health ser-
vices were obtained at enrollment and at 6-month intervals during the 3-year
follow up. Cohorts of remitters versus non-remitters at enrollment were created
using established criteria. Total costs for remitters and non-remitters were com-
pared using mixed-effects models with and without MI based on Markov chain
Monte Carlo with multivariate normality assumption (MI-MCMC) or fully condi-
tional specification with predictive mean match method (MI-FCS). All analyses on
costs were adjusted for patient’s demographics and comorbidities. RESULTS: The
majority of the patients were male (61.6%) and non-remitters (73.8%) with a mean
age of 42 years. Out of 2282 patients, 41.2% had at least 1 visit (out of 7 visits) with
missing costs data. Without MI, the total healthcare costs were estimated to be
$8689.6 for the non-remitters and $6730.0 for the remitters with a difference of
$1959.7 (95% CI: $790 - $3129.4) over a 6-month period (p0.001). The estimated
differences in total costs between remitters and non-remitters were $1763.3 over
the 6-month period with the MI-MCMC method (p0.004) and $1483.9 with the
MI-FCS method (p0.009). CONCLUSIONS: Significant differences in total costs
between remitters and non-remitters were obtained from this study using mixed-
effects models with and without MIs. Further analysis will be conducted to explore
MI for estimation of other costs and examine missingness mechanisms.
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VALIDITY OF ADMINISTRATIVE CLAIMS DATA FOR CALCULATING ADHERENCE
MEASURES FOR LONG-ACTING INJECTABLE (LAI) ANTIPSYCHOTIC THERAPIES
Kozma CM1, Durham M2, Durkin M3, Dickson M4, Howe A3
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OBJECTIVES: To examine sources of error in claims-based adherence calculations
for LAI antipsychotics with potentially invalid days’ supply (DS) values and evalu-
ate the assumption that quantity-dispensed (QD) values are in product units.
METHODS: Pharmacy claims for single-dose LAI antipsychotics dispensed between
January 1, 2009 and December 31, 2010 were selected from a large US database.
Frequency distributions were generated for observed DS and QD values for each
product and dose. Observed QD values on premixed LAI antipsychotic claims were
divided by the product’s volume to test the assumption that QD was entered in
milliliters rather than units. After adjustment toQD for premixed LAI antipsychotic
claims, duration of therapy per injection was calculated for all LAI antipsychotics
as DS/QD. Calculated therapy duration was compared with the dosing interval in
the product’s package insert (PI). Percentage of claims with duration of therapy per
injection within the product’s PI range was calculated as a measure of the validity
of the observed DS value. RESULTS: For the 611,325 LAI antipsychotic claims ana-
lyzed, observed QD values ranged from 0.01 to 117, suggesting values that did not
always represent product units. After adjustment to QD for premixed LAI antipsy-
chotics, 98.5% of claims had an integer value for calculated quantity in product
units, supporting the assumption that premixed LAI antipsychotics’ quantities
were entered in milliliters. After adjustment, 21.5% of claims had a calculated
therapy duration per injection outside the PI range. Percentage of claims with
calculated therapy durations outside the PI ranged from 10.6% to 39.1% for pali-
peridone palmitate, 7.6% to 13.1% for risperidone long-acting injection, and 3.1% to
10.8% for olanzapine pamoate. CONCLUSIONS: Results raise concerns regarding
potentially invalid values in DS andQDfields. Algorithms for appropriate use of LAI
antipsychotic pharmacy claims in adherence calculations, quality measurement,
and cost analyses are recommended.
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AN APPLICATION OF GROUP-BASED MODELING APPROACH FOR TRAJECTORY
RECOGNITION: THE DEVELOPMENTAL COURSES OF HYPERACTIVITY AND
INATTENTIVE SYMPTOMS
Cheng W1, Goodwin R2, Wu P2, Vitaro F3, Tremblay R4
1Analysis Group, Inc., Boston, MA, USA, 2Columbia University Mailman School of Public Health,
New York, NY, USA, 3University of Montreal School of Psycho-Education, Montreal, QC, Canada,
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OBJECTIVES: Uncertainty remains regarding the developmental courses of inat-
tentive (IN) and hyperactivity (HA) symptoms. Using group-based trajectory mod-
eling, we sought to identify distinct independent and joint IN/HA symptom trajec-
tories and their predictors. METHODS: A total of 1037 boys (mean age: 6.20.3
years) from low socioeconomic areas in Montreal were recruited in 1984 for the
Longitudinal and Experimental Study of Low Socioeconomic Status (SES) Boys in
Montreal. Teacher and mother ratings of subjects’ IN and HA symptoms were
collected annually at ages 6, and 10 to 15 using the Social Behavior Questionnaire,
where the higher of the two raters’ scores was taken as subject’s IN/HA score.
Numbers and probabilities of independent IN and HA trajectories were identified
using group-based semi-parametric mixture models. Joint IN/HA trajectories were
then constructed as the joint probabilities of independent IN/HA trajectories.
Multinomial logistic regressions were conducted to assess baseline parental and
subject behavioral problems as predictors of joint trajectories. RESULTS: Six and
five independent trajectories were generated for IN and HA symptoms, respec-
tively, constituting 30 joint trajectories. The most common independent IN trajec-
tory (29.5% of study sample) had a moderate number of IN symptoms at baseline
that increased slightly with age (moderate-slightly rising), whereas the most com-
mon independent HA trajectory (28.5%) was baseline moderate-sharply declining.
The most common joint trajectories were based on the co-occurrence of a moder-
ate-sharply rising IN trajectory, and a low-/moderate-slightly rising HA trajectory
(17% vs. 14%). Subjects’ aggressiveness, conduct-, oppositional-, and anti-social
problems (p0.001), and paternal SES (p0.01) were significant predictors of joint
trajectories. CONCLUSIONS: Group-based trajectory modeling may be a useful
time-dependent pattern recognition tool. It enabled the identification of distinct
independent and joint IN/HA trajectories in age-related developmental courses.
Assessing baseline behavioral problems and paternal SES may help identify and
target interventions for young boys at risk of high-level IN/HA symptoms early on.
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TIME-ON-THERAPY FOR ATYPICAL ANTIPSYCHOTICS IN A MARKOV COHORT
ANALYSIS
Rajagopalan K1, O’Day K2, Meyer K2, Pikalov iii AA3
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OBJECTIVES: To demonstrate a unique approach to modeling long-term time-on-
therapy and cardiovascular disease (CVD) outcomes of patientswith schizophrenia
treated with atypical antipsychotics (AAPs). METHODS: A 5-year Markov cohort
analysis among adult patients with schizophrenia was undertaken to compare
time-on-therapy and CVD outcome differences lurasidone, generic-olanzapine,
aripiprazole, quetiapine, and ziprasidone. Modeled health states were: patients on
initial AAP; patients switched to a second composite-AAP; and patients on clozap-
ine after failing a second composite-AAP. The composite-AAP health state simu-
lated frequent treatment switching and was operationalized by averaging out-
comes, costs, and discontinuation rates (for transition probabilities) of the AAPs.
Patients discontinuing composite-AAP due to lack of efficacy were switched to
clozapine. Time-on-therapy was modeled using sub-states based on time of
switching. Baseline characteristics of themodeled cohort, data for discontinuation
rates, and averageweight changewere obtained fromCATIE, a comparative clinical
trial of lurasidone vs quetiapine XR, and an open-label study comparing aripipra-
zole and olanzapine. Relative risk of diabetes obtained from a retrospective anal-
ysis predicted CVD events using Framingham BMI risk equations. RESULTS:Over 5
years, patient time-on-therapy for the initial-AAP, composite-AAP, and clozapine,
respectively, was 0.85, 3.13, 1.01 years (lurasidone); 1.00, 2.98, 1.02 (generic-olan-
zapine); 0.51, 3.41, 1.08 (aripiprazole); 0.47, 3.45, 1.08 (quetiapine); and 0.54, 3.37,
1.09 (ziprasidone). In a 10,000 patient cohort, there were 407, 434, 415, 416, and 412
CVD events, respectively, in the lurasidone, generic-olanzapine, aripiprazole, que-
tiapine, and ziprasidone arms. CONCLUSIONS: This long-term Markov cohort
model simulates multiple treatment switches by using a composite health state
from sub-states and also enabled outcome assessment of time-dependent patient
characteristics, such as CVD events. The results were consistent with published
Markovmicro-simulationmodels showing that lurasidone and generic-olanzapine
had favorable discontinuation rates and that lurasidone and ziprasidone had fewer
CVD events. This analysis represents an effective alternative for modeling cohort-
level outcomes.
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CROSS-CULTURAL ADAPTATION OF A RESEARCH VERSION OF THE REY
AUDITORY VERBAL LEARNING TEST (RAVLT) INTO (US) SPANISH
Rendu E1, Caveney A2, Miner A3, Nomikos A3, Acquadro C4
1MAPI Institute, Lyon, France, 2University of Michigan, Ann Arbor, MI, USA, 3Cogstate, New
Haven, CT, USA, 4MAPI Research Trust, Lyon, France
OBJECTIVES: The Rey Auditory Verbal Learning Test (RAVLT) was developed to
evaluate verbalmemory. The standard form comprises a 15-word list (List A) learn-
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ing task with five trials and an interference list (15 new words – List B) read to the
subject after the fifth trial of List A. The original RAVLT also includes a recognition
trial in which subjects are asked to identify List A words from a larger list of words
that includes distractor words. In most versions of the RAVLT, the distractor list is
comprised of words from List B as well as other words, most having either a se-
mantic and/or a phonetic link with words from Lists A and/or B. The objective of
this abstract is to present the translation process of the RAVLT into US Spanish (six
pairs of recall lists and six recognition lists). METHODS: For the recall words, a
direct translation, in collaboration with a speech therapist and a neuropsycholo-
gist, was recommended, with frequency of use similar to the original as well as
word length (1 syllable or 2 syllables and 2 characters). For the recognition
words, the translations had to respect the semantic and phonetic links to the recall
words. RESULTS: Fifty out of 180 words from the recall lists raised discussions
because of difficulties in finding translations with the appropriate word length.
Thirty-four out of 120 words from the recognition list proved difficult to translate
because of problems in finding direct translations that respected the phonetic or
semantic links to the recall words. For instance, the recognition word “Balloon,”
with a phonetic link with “Moon” (List A #1), was “translated” as “Lona” (Tarp) to
keep the phonetic link with “Luna” (Moon). CONCLUSIONS: This methodology en-
abled production of a US Spanish version of the RAVLT respecting the intent of the
original US English.
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THE IMPACT OF METHODOLOGY ON RESULTS OF OBSERVATIONAL STUDIES:
AN EXAMPLE FROM STUDIES EVALUATING OUTCOMES OF PRENATAL
ANTIDEPRESSANT EXPOSURE
Shen X, Raisch DW
University of New Mexico College of Pharmacy, Albuquerque, NM, USA
OBJECTIVES: To review the methodology of studies evaluating pregnancy/birth/
child development outcomes of prenatal antidepressant exposure (PAE) and, when
appropriate, assess the impact on study results usingmeta-regression.METHODS:
A Medline search was conducted up to October 2011, restricting to English and
human literature. The MeSH term “antidepressive agents,” was combined with
MeSH terms for spontaneous abortion, preterm birth(PB), birth weight, small for
gestational age, or poor child development. We added relevant articles from refer-
ence lists of reviews and included studies. We proposed that antidepressant class,
type of data source, adjustment for maternal depression, exposure definition, du-
ration and timing, and adjustment for more than three covariates would impact
study results. Cochran’s Q statistic was used to test for heterogeneity of results.
When heterogeneity existed, meta-regression using a random-effects model was
performed to examine the impact of different methodological choices on study
results. Meta-regression is a regression analysis in which each study is a unit of
observation and the effect estimate is regressed on study characteristics.RESULTS:
Of 33 studies included, we found differences in the definition of PAE, data sources,
and covariates adjusted. Thirteen studies focused on selective serotonin reuptake
inhibitors. Five studies defined exposure as one prescription of antidepressant
during pregnancy versus 13 studies required PAE for at least one trimester. Preg-
nancy information services, birth registries, and referrals from hospitals/clinics
were the most common data sources. Only 10 studies adjusted for maternal de-
pression. Cochran’s Q was only significant for PB. Meta-regression showed that
adjusting for more than three covariates significantly (p0.02) impacted pooled
odds ratios (POR). POR for PB was 1.39 (95% confidence interval (CI)1.27-1.52) for
studies with 3 or more covariates versus 1.82(95% CI1.43-2.29) for other studies.
CONCLUSIONS: Methodological variations can make pooling of observational
studies inappropriate. Consistency of study methodology should be assessed be-
fore combining studies even if heterogeneity were absent.
SYSTEMIC DISORDERS/CONDITIONS – Clinical Outcomes Studies
PSY1
HOSPITALIZATION COSTS ATTRIBUTABLE TO OBESITY IN PATIENTS WITH
ADVERSE DRUG EVENTS IN US HOSPITAL FOR 2001-2009
Lee SM1, Choi IS2, Yi SY2, Kim YS2, Suh DC1
1College of Pharmacy Chung-Ang University, Seoul, South Korea, 2Rutgers University,
Piscataway, NJ, USA
OBJECTIVES: To estimate hospitalization costs attributable to obesity (CAO) in pa-
tients with adverse drug events (ADE) in the US hospital. METHODS: The study
used the Nationwide Inpatient Sample (NIS) of the Healthcare Cost and Utilization
Project (HCUP) from 2001 to 2009. The NIS includes sampling weight and design
variable for generating national representative estimates. ADE were defined as
poisoning due to inappropriate uses or medication errors, and an adverse drug
reaction. The cost to charge ratios were applied to estimate hospitalization costs
using the hospital charge. The recycled prediction method was employed to esti-
mate CAO. This method estimated parameters by running a generalized linear
model with log link function and gamma distribution of hospital costs on all the
study variables. CAO was defines as the differences between the predicted mean
hospitalization costs for obese patients with ADE and the predicted mean hospi-
talized costs if obese patients with ADE could be a normal weight patients with
ADE. All costs were converted to 2010 US dollars. RESULTS: A total of 2,177,755
admissions due to ADE were identified. Among these admissions, 4.3% of them
were obese patients. Obese patients were older than non-obese patients (46.6 vs.
43.7, p0.001) and stayed longer in hospital than non-obese patients (3.4 vs. 2.9
days, respectively). The average hospitalization costs were $9099 (95%CI:$8,926-
$9272) for obese and $8014 (95%CI:$7978-$8051) for non-obese patients. Overall, the
average CAO in patients with ADEwas predicted to be $725 (95%CI:$720-$729) after
adjusting for patients characteristics and comorbidities. CAO were increased as
patients age increased from $457 (95%CI:$446-$468) for age 0-17 years old to
$1,051($993-$1,110) for age85years old. CONCLUSIONS: Obese patients with ADE
have significantly higher hospitalization costs compared to non-obese patients
with ADE. Since the additional costs due to obesity are avoidable, the additional
efforts to lose weight are strongly recommended.
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ADVERSE EVENT BURDEN, RESOURCE USE AND COSTS ASSOCIATED WITH
IMMUNOSUPPRESSANT THERAPY FOR THE TREATMENT OF SYSTEMIC LUPUS
ERYTHEMATOSUS: A SYSTEMATIC LITERATURE REVIEW
Shaul A1, Pokora T1, Paramore C2, Cragin LS1, Weinstein A3, Dennis GJ4, Narayanan S4,
Oglesby AK5
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OBJECTIVES: To quantify the incidence of adverse events (AEs), identify discontin-
uation rates due to AEs, and determine the cost and resource use associated with
AEs from azathioprine (AZA), cyclophosphamide (CYC), mycophenolate mofetil
(MMF),methotrexate (MTX), and cyclosporine (CsA) in patientswith systemic lupus
erythematosus (SLE). METHODS: A systematic review of English-language, MED-
LINE- and EMBASE-indexed literature published between January 1980 and Sep-
tember 2011 was conducted using terms related to SLE, AEs, discontinuation, re-
source use and costs.RESULTS:This review identified 38 publications reporting the
burden of AEs related to AZA, CYC, MMF, MTX or CsA. The incidence of AEs ranged
from 42.8% to 97.3%. Common AEs included infections, gastrointestinal AEs and
amenorrhea. In direct comparisons, AZA was associated with more hematological
cytopenias than MMF (26.9% vs. 3.8%, respectively) based on one study. CYC was
associated with more infections than MMF (40-77% vs. 12.5-32%, respectively) or
AZA (17-77% vs. 11-29%, respectively), and it was also related tomore gynecological
toxicities than MMF (32-36% vs. 3.6-6%, respectively) or AZA (32-71% vs. 8-18%,
respectively). However, other studies reported no difference in AEs associatedwith
CYC compared to either AZA or MMF, or with AZA compared to CsA. Discontinua-
tion rates due toAEswere 0–17% in short-term randomized controlled trials (RCTs),
2.3–44.4% in long-term RCTs, and 1.9–21.8% in observational studies. The rate of
hospitalized infections was similar between patients taking MMF and AZA (1 day
per patient-year in each group), but higher for those taking CYC (10 days per pa-
tient-year). No studies reported costs associated with AEs. CONCLUSIONS: The
incidence of AEs associatedwith SLE immunosuppresantswas consistently high as
reported in the SLE literature,while discontinuation due to theseAEswidely varied.
Studies describing costs and resource use associated with these AEs were sparse
and warrant further study.
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ADVERSE EVENTS ASSOCIATED WITH ANTI-TNF-ALPHA- AGENTS: A
PHARMACOVIGILANCE STUDY
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OBJECTIVES: Anti-tumor necrosis factor (TNF) medications have revolutionized
the treatment of autoimmune diseases. They are associated, however, with a wide
range of serious adverse events (AE). The objectives of this study were to describe
the potential serious AEs associatedwith anti-TNFmedications and compare them
with the AEs associated with concomitant use of methotrexate and corticosteroids
in US.METHODS:The study anti-TNFmedications included infliximab, etanercept,
adalimumab, certolizumab pegol and golimumab. The FDAAdverse Events Report-
ing System (AERS) database was utilized to determine the overall frequency of
adverse events involving anti-TNF medications. The data from 1998 to 2010 were
used to analyze the trend of AEs. Due to the complexity of the database, AEs re-
ported in 2009, were selected for detailed measurement and comparison as a per-
cent of reported events within the drug classes. All AEs involving anti-TNF medi-
cations, corticosteroid and methotrexate (MTX) monotherapy and in combination
with MTX and/or corticosteroids were analyzed and compared in this analysis.
RESULTS: A substantially higher number of AEs were reported for anti-TNF medi-
cations compared tomethotrexate or corticosteroidmonotherapy. A total of 36,245
AE reports in 2009, including 24,166 (67%) for anti-TNF, 6,164 reports for anti-TNF/
MTX and 2,867 for anti-TNF/corticosteroids. There was an increased frequency for
a range of anti-TNF-associated AEs among those patients who were also taking a
combination of anti-TNF plus corticosteroid and an even greater increase in pa-
tients taking the three drug combination (anti-TNF/MTX/corticosteroid). Themajor
reported AEs associated with anti-TNF are infectious complications, cancer risk,
death or disabling outcome, neurological and cardiac pathology. CONCLUSIONS:
There is a significant risk of AE associated with anti-TNF and the proportion of AEs
may behigher if patients received combination therapywithMTXor corticosteroid.
It is important to have a drug safety sentinel for unknown AEs associated with
anti-TNF agents.
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PREVALENCE OF AUTOIMMUNE DISEASES AND OTHER COMORBIDITIES IN
PATIENTS WITH PSORIASIS IN THE UNITED STATES
Zhang F1, Guerin A2, Gauthier G2, Day R1, Khan Z1
1Celgene Corporation, Summit, NJ, USA, 2Analysis Group, Ltee., Montreal, QC, Canada
OBJECTIVES: To estimate the comorbidity burden of patients with Pso, with a
particular focus on autoimmune diseases.METHODS: In a large US representative
administrative claims database (2004-2008), we identified adult patients with 2
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